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BMT = bone marrow transplantation; IFN = interferon; IL = interleukin; NOD = non-obese diabetic; SLE = systemic lupus erythematosus; Th = T
helper; Tregs = regulatory T cells.
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Autoimmunity induced by lymphopenia
More than 30 years ago, the occurrence of spontaneous
autoimmune thyroiditis was observed in rodents that were
made severely T-cell lymphopenic by neonatal thymectomy
or by thymectomy at week five after birth together with
concomitant low dose irradiation [1,2]. Following these
reports, numerous studies have shown that manipulations
that generate functional T-cell lymphopenia result in the
development of a variety of organ-specific autoimmune
diseases in animal models (reviewed in [3]). Impressive
examples of such manipulations include: IL-2 knockout
mice, that develop prominent autoimmune colitis [4]; T-cell
receptor-alpha chain deficient mice, that develop
inflammatory bowel disease associated with an array of
autoantibodies [5,6]; T-cell receptor-α chain transgenic
mice [7]; neonatal application of cytotoxic intervention
protocols, such as cyclosporine A [8]; total lymphoid
irradiation [9] or thymectomy [10]; and lymphotoxic
treatment of adult animals [11].
It was subsequently found that adoptive transfer of T cells
into congenic immunocompromised hosts initiated the
spontaneous development of aggressive inflammatory
autoimmunity in recipients [12]. Further studies revealed that
the development of autoimmunity in hosts was critically
dependent on both transfer of alpha/beta CD4-positive T
cells and T-cell deficiency in the recipients. Together, these
data indicate that lymphopenia promotes the induction of
autoimmune inflammation by self-reactive syngeneic
peripheral blood CD4 T cells. Indeed it could be
demonstrated that when lymphopenia was induced in mice
by cytotoxic treatment with cyclophosphamide or
streptozotocin, the peripheral T-cell population that emerged
consisted mainly of IFN-γ secreting proinflammatory Th1-like
cells [13]. However, it was unclear whether the appearance
of these cells reflected de novo priming of autoreactive
inflammatory T cells in the lymphopenic host or the
preferential outgrowth of pre-existing T cells of autoimmune
specificity, facilitated by a breakdown of suppressive
mechanisms. Thus, the critical question for the
understanding of autoimmunity, namely how the causative
autoimmune response was initiated, remained unresolved.
Recent studies have shed light on the mechanisms that
lead to the breakdown of peripheral tolerance in lympho-
penic animals. Powrie and her group demonstrated that
colitogenic inflammatory CD4 T cells exist in normal mice
[14]. Importantly, their function is controlled in healthy
animals by regulatory mechanisms involving IL-10 and a
distinct subset of CD4 T cells characterized by the
expression of CD25. Moreover, adoptive transfer of these
CD25-positive CD4 T cells prevented T-cell-mediated
immune pathology and even ameliorated established
gastrointestinal inflammation in the CD4 CD45RBhigh
T-cell transfer model of inflammatory bowel disease [15].
These findings emphasize that autoreactive T cells are
part of the normal peripheral T-cell repertoire and that their
control is an active process mediated by the CD25-
expressing subset of CD4 T cells. 
CD25-positive CD4 T cells with regulatory capacity have
been described by Sakaguchi and colleagues as a
population of thymus-derived CD4 T cells in the peripheral
blood that prevents the occurrence of a variety of organ
specific autoimmune diseases primarily affecting
endocrine organs and the gastrointestinal tract [16].
CD25-positive T cells with regulatory capacity have
therefore been denoted regulatory T cells (Tregs) or
naturally occurring regulatory T cells. 
Sakaguchi’s group recently reported that CD25 Tregs can
be characterized by the expression of the transcription
factor Foxp3 and that retroviral expression of Foxp3
converts naive T cells towards a regulatory phenotype
resembling that of naturally occurring Tregs [17]. Of
interest, adoptively transferred Foxp3-expressing T cells
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prevent autoimmune colitis and gastritis in the CD4
CD45RBhigh T-cell transfer model. These results clearly
indicate that in healthy individuals a delicate balance exists
between pathogenic autoreactive T cells and the
regulatory T-cell population that keeps them in control. In
lymphopenia this balance is perturbed and the outgrowth
of autoantigen-specific, proinflammatory T cells is
facilitated by the depletion of the regulatory T-cell subset.
A recent publication by Sarvetnick and her group now
offers a distinct facet to the concept of controlling the
emergence of autoreactive T cells in the periphery [18].
The authors observed that diabetes-prone non-obese
diabetic (NOD) mice are lymphopenic and have reduced
numbers of T cells compared to non-autoimmune strains,
such as wild type BALB/c mice, NOD MHC-matched B10
mice and congeneic B6.Idd3.NOD mice that contain a
0.35 centimorgan protective interval from B6 mice and do
not develop diabetes. They found that increasing T cell
numbers in the mice by immunization with non-specific
activators of the immune system, such as mycobacterial
cell wall constituents (e.g. complete Freud’s adjuvant),
protected NOD mice from developing diabetes, indicating
a correlation between increased T-cell numbers and
disease protection. In accordance with this hypothesis,
the injection of excess CD4 T cells from NOD mice into
pre-diabetic NOD littermates prevented the development
of diabetes in the recipients.
Injecting labeled T cells specific for pancreatic β cells into
pre-diabetic NOD mice revealed that the transferred T
cells vigorously proliferated in the lymph nodes of
recipient NOD mice, but not in the lymph nodes of NOD
mice that had elevated T cell numbers because of
infusions of syngeneic excess T cells or immunization with
complete Freud’s adjuvant. The authors assessed cell
surface receptors to distinguish between conventionally
activated T cells and T cells that expand homeostatically.
They demonstrated that a significant fraction of T cells in
autoimmune NOD mice expand homeostatically and that
the expansion correlates with autoimmune inflammation,
e.g. lymphocytic infiltration of pancreatic islets. As
homeostatic expansion is tightly regulated by the available
space in lymphoid organs [19], the authors conclude from
their data that a depleted memory T-cell compartment
fuels the generation of autoreactive effector cells in
lymphopenic diabetogenic NOD mice. The particular role of
CD25-positive Tregs or other T cells with a regulatory
capacity in those mice that had higher T cell numbers and
did not develop diabetes was not specifically addressed in
the study; however, the data suggest that organ-specific
autoimmunity is initiated by lymphopenia and compensatory
homeostatic expansion of autoreactive T cells.
Human autoimmune diseases and lymphopenia
Lymphopenia is not uncommon in several human
autoimmune diseases. Reduced total lymphocyte counts
are observed in rheumatoid arthritis, insulin-dependent
diabetes mellitus, Crohn’s disease, systemic lupus
erythematosus (SLE) and primary vasculitides. Similarly,
primary Sjogren’s syndrome is associated with severe
lymphopenia in 5% of patients, and the relative risk for CD4
T-cell lymphocytopenia in patients with Sjogren’s syndrome
has been estimated to be between 3.4 to 6000 [20,21].
Patients exposed to silica show a significant reduction of
peripheral blood lymphocytes besides the well-established
increased risk of autoimmune phenomena [22]. However, it
is noteworthy that lymphopenia was observed in 48 out of
53 silicotic subjects while only 10% developed overt
clinical autoimmune disorders [22]. Thus, other genetic or
environmental factors are likely to have been involved in the
development of autoimmune diseases in patients
investigated in that study.
Lymphopenia constitutes one of the disease criteria in the
American College of Rheumatology classification of SLE.
It is, however, extremely difficult to determine whether
lymphopenia is the cause or the consequence of systemic
autoimmunity involving bone marrow in this context.
Indeed the concomitant decrease in thrombocyte and
erythrocyte blood counts in SLE patients might argue in
favor of bone marrow deprivation as a result of lupus
activity and against lymphopenia as the cause of the
autoimmune inflammation.
Systemic inflammation per se affects peripheral blood cell
counts, and increased numbers of circulating activated
lymphocytes have been detected in almost every human
autoimmune disease. Consequently, actual peripheral
blood cell counts may reflect organ involvement in the
underlying disease, systemic disease activity as well as
immunosuppressive therapy.
The relationship between hematologic abnormalities and
autoimmunity in humans was explored further by comparing
patients with insulin-dependent diabetes mellitus and their
first-degree relatives and healthy controls [23]. In contrast
to a priori expectations, CD4 T-cell counts were normal in
patients and significantly elevated in their non-diabetic first-
degree relatives. Another argument against a causative role
for lymphopenia in human autoimmune diseases derives
from the observation that lymphopenia following infections
with bone marrow-depriving viruses, malnutrition or drug-
induced bone marrow toxicity is not commonly complicated
by autoimmune manifestations.
The hypothesis that lymphopenia may not be sufficient for
human autoimmune disease development is further
supported by wide experience with ablative chemotherapy
and autologous bone marrow transplantation (BMT) for
malignant diseases. Although various autoimmune
phenomena, including SLE, thyroiditis, thrombocytopenic180
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purpura, hemolytic anemia, Guillain-Barré syndrome, acute
disseminated encephalomyelitis and myasthenia gravis
[24,25], have been documented following autologous BMT,
the incidence of such cases is rather low. In contrast,
several reports have highlighted the beneficial effect of
autologous BMT that was performed for the treatment of
malignancies on coexisting autoimmune diseases [26,27]. It
is evident from these observations, and BMT studies in
animal models of autoimmune disease, that the best results
with regard to clinical remission of autoimmune inflammation
required the strongest lympho-myeloablative regimens [26].
Based on these studies, autologous BMT has now
successfully been applied as therapy for several refractory
autoimmune diseases [28]. The impressive results obtained
with high dose lympho-myeloablative conditioning regimens
are in accordance with the concept that autoimmune
diseases are maintained by activated autoreactive T cells
which have to be eliminated as thoroughly as possible to
achieve complete and lasting remission.
Conclusion
As autoreactive T cells are part of the normal peripheral T-
cell repertoire, it is conceivable that their expansion and
activation in situ governs the development of autoimmune
disease. Homeostatic expansion of autoreactive T cells is
controlled in healthy individuals by space limitation, and
their activation is regulated by specialized T-cell subsets. In
lymphopenic animals, homeostatic expansion is enhanced
as a mechanism of compensation, resulting in spontaneous
autoimmune phenomena. Lymphopenia, however, although
frequently associated with autoimmune diseases, appears
not to be sufficient for the development of human
autoimmunity, which may require additional environmental
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